About
About journalGoals and objectives of the journalEditorial council
Archive
To authors
Procedure for reviewingRequirements for publicationsSend articlePrivacy DeclarationConflicts of Interest DeclarationCriteria for authorship
SubscriptionEthical StandardsContacts
About
About journalGoals and objectives of the journalEditorial council
Archive
To authors
Procedure for reviewingRequirements for publicationsSend articlePrivacy DeclarationConflicts of Interest DeclarationCriteria for authorship
SubscriptionEthical StandardsContacts
Logout
Year
202420232022202120202019201820172016201420132012201120102009200820072006200520042003200220012000
Edition number
№20 (313)№19 (311)№18 (311)№s4-15№17 (310)№16 (309)№15 (308)№14 (307)№13 (306)№s3-15№12 (305)№11 (304)№10 (303)№9 (302)№s2-15№8 (301)№7 (300)№6 (299)№s1-15№4 (297)№3 (296)№2 (295)№1 (294)

№5 (298) / 2015

M.B. Antsiferov
CLINICAL INERTIA IN THE THERAPY OF TYPE 2 DIABETES MELLITUS
5-11
T.Yu.Demidova
SGLT 2INHIBITORS: PHARMACOLOGICAL GLYCOSURIA AS A NEW APPROACH TO THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
12-18
A.M. Mkrtumyan
ALOGLIPTIN – EFFECTIVE AND SAFE DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN THE THERAPY OF TYPE 2 DIABETES MELLITUS
20-27
N.I.Volkova, M.I. Porksheyan
PERSONALIZED APPROACH TO THE REGIMEN OF INSULINOTHERAPY - IS THERE A PLACE FOR FEAR OF HYPOGLYCEMIA?
28-31
N.A. Chernikova, L.P. Ivanova, F.T. Abaeva
ADVANTAGES OF TIMELY INITIATION OF INSULIN THERAPY. RESULTS OF THE RUSSIAN OBSERVATIONAL PROGRAM HUBIN
32-37
A.F. Verbovoy, E.V. Mitroshina, Sharonova L.A.
ADIPOKINES AND CARDIOVASCULAR DISEASES
38-43
A.S. Ametov
ADVANTAGES OF FIXED COMBINATION OF SAXAGLIPTIN AND METFORMIN WITH MODIFIED RELEASE (KOMBOGLYCE PROLONG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
44-52
M.B. Antsiferov (1), V.S.Pronin (2)
THE USE OF CLINICAL AND LABORATORY PREDICTORS FOR PROGNOSTICATION OF ANTISECRETORY AND ANTIPROLIFERATIVE EFFECTS OF SOMATOSTATIN ANALOGUES DURING THE TREATMENT OF ACROMEGALY: REVIEW OF RECENT RESEARCH
53-60
M.B. Antsiferov, O.M. Koteshkova
EFFICIENCY OF TRIPLE THERAPY USING LIRAGLUTIDE (VICTOZA) - FIRST LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND VISCERAL OBESITY
61-66
O.L. Badalyan, A.A. Savenkov
POLYNEUROPATHY: CLINICAL MANIFESTATIONS, CLASSIFICATION, THERAPY
67-71

OSTEOPOROSIS

I.Yu. Golovach
SKLEROSTIN AND ITS INHIBITORS - A NEW CONCEPT IN THE TREATMENT OF BONE DISORDERS: CERTAIN PAST, PROMISING FUTURE
72-77
A.Yu. Kochish, S.N. Ivanov, E.V. Sannikova
ADHERENCE TO THE DIAGNOSIS OF OSTEOPOROSIS IN PATIENTS WITH LOW-ENERGY FRACTURES
78-82
A.Yu. Kochish, S.N. Ivanov
CASE OF OSTEONECROSIS OF THE MAXILLA IN PATIENT WITH POSTMENOPAUSAL OSTEOPOROSIS AGAINST THE BACKGROUND OF PROLONGED TREATMENT WITH ANTIRESORPTIVE DRUGS
83-87
G.Sh.Golubev (1), V.A. Grebenschikov (2)
EFFECT OF THERAPY WITH STRONTIUM RANELATE ON THE TREATMENT OUTCOME IN PATIENTS WITH LOW-ENERGY FRACTURES OF THE ANKLE
88-95
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.